The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

ANI Pharmaceuticals made a recommended cash offer of about 5.3 billion kronor for Egetis Therapeutics, maker of Emcitate (tiratricol); the acceptance period is expected to open around November 20. Braveheart and Hengrui reported 52-week open-label data, with no comparison group, for oral BHB-1893 in adults with symptomatic obstructive HCM: 33 of 42 had a provoked gradient below 30 mmHg and 24 ended on the starting dose. Also: Amgen's real-world Repatha (evolocumab) vs. ezetimibe study; Lilly and Hims & Hers on Zepbound (tirzepatide) and Foundayo (orforglipron) self-pay access; Agios R&D role cuts; Moderna's norovirus cohort decision; and its Q3 revenue and raised outlook. This is the original Friday, November 6 edition, released late.

J&J's Rybrevant Faspro (amivantamab) won accelerated FDA approval in later-line head and neck cancer on a 42% single-arm response rate. A HOVON trial adding Tibsovo (ivosidenib) to intensive chemotherapy in IDH1-mutated AML showed a large interim event-free survival gain, though overall survival is not reported. The daily roundup covers ASH detail on Genmab and AbbVie's epcoritamab plus lenalidomide in lymphoma and Pfizer's Elrexfio (elranatamab) in myeloma, Boehringer Ingelheim's staged six-program deal with SBP Group, and the FDA's Nov 6 Zolgensma cancer-risk alert in spinal muscular atrophy. Akebia's VOCAL trial of Vafseo (vadadustat) in dialysis anemia closes this original November 5 edition, released on a delayed schedule.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

CVS Health plans to split into two public companies, separating about 9,000 pharmacies from Aetna and Caremark, targeting the first half of 2028. This delayed November 4 edition also covers AbbVie's IBD license for Nxera's gut-targeted NXE0033744: $100 million upfront, up to $1.37 billion in milestones, and no IBD efficacy results in the announcement. In the roundup: FDA priority review for BeOne's Brukinsa (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, and Pfizer's November 3 snapshot of discontinued obesity, PAH and KRAS programs. Plus Novo Nordisk's diverging Q3 operating profit measures and FDA Breakthrough Therapy designation for Idorsia's daridorexant in pediatric insomnia.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Fresenius gains exclusive access to up to 37 biosimilar candidates through WuXi Biologics, with initial development expected on biosimilars of polatuzumab vedotin and teprotumumab. Supernus and Indivior complete their merger, leaving former Indivior holders with about 56.5% of Supernus, Inc., while a separate $1 billion dividend is partly funded by a loan to the combined company. In neurology, Bright Minds reports an FDA partial hold on a planned BMB-101 Phase 2 study, Tiziana reports INFORM-MS data for foralumab, and Novartis ends a BrainTransporter deal with BioArctic. This delayed November 2 edition cites Samsung Biologics' later November 5 definitive figures: 97.66% of PolyPeptide's issued share capital and voting rights tendered.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Servier's sevasemten missed its pivotal Becker muscular dystrophy trial, while Karyopharm filed Chapter 11 and proposed an Ayrmid deal around XPOVIO. This delayed November 3, 2026 edition reports dated developments: 'today' means November 3 and 'Monday' November 2. Also covered: uniQure's AMT-130 application, Teva's TOPAS-MSA stop, FDA potency guidance, InventisBio's psoriasis results, Recursion's REC-4881 data, Dr. Reddy's tentative lenacapavir approval reported by CHAI, Rhythm's LG Chem amendment and Pfizer's forecast.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.